AbbVie Presents New Efficacy Data on Upadacitinib

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib ...

The analysis evaluated the efficacy of upadacitinib (15 mg or 30 mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by ...

AbbVie Presents Long-Term Data Further Supporting the Efficacy ...

Upadacitinib (15 mg and 30 mg) was generally well tolerated, and the safety data in the long-term extension of the three studies were consistent ...

AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate ...

AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate to Severe Atopic Dermatitis, High-Impact Areas ... A new analysis from phase 3 ...

AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in ...

SELECT-PsA 2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of ...

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority ...

Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.

AbbVie Presents Long-Term Data Further Supporting the Efficacy ...

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying ...

AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in ...

Discovered and developed by AbbVie scientists, RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory ...

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II ...

The relationships between upadacitinib, an oral selective Janus kinase 1 inhibitor, plasma exposures, and its efficacy (assessed by the American College of ...

AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib ...

AD Up is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety and efficacy ...

Efficacy and safety of upadacitinib in patients with rheumatoid ...

Approximately 47% of all patients who began in high disease activity demonstrated a CDAI improvement >12 at week 260 with upadacitinib 15/30 mg.

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in ...

Discovered and developed by AbbVie, upadacitinib is an investigational oral agent engineered to selectively inhibit JAK1, which plays an important role in the ...

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed ...

Upadacitinib 15 mg was generally well tolerated, with no new safety signals identified in this GCA population.1 Discontinuations due to adverse ...

Long-term safety and efficacy of upadacitinib versus adalimumab in ...

Conclusion The safety profile of upadacitinib through 5 years was consistent with the known safety profile of upadacitinib, with no new safety risks. Clinical ...

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ ...

AbbVie previously announced top-line data from SELECT-COMPARE showing that RINVOQ 15 mg met the primary endpoints of ACR20 response and ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

Findings In this analysis of follow-up data from the large, global, replicate phase 3 Measure Up 1 and Measure Up 2 randomized clinical trials ...

Safety and effectiveness of upadacitinib or adalimumab plus ...

In patients with rheumatoid arthritis (RA) who do not respond sufficiently to biologic disease-modifying antirheumatic drug (bDMARD) treatment with Janus kinase ...

AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary ...

At week 24, upadacitinib achieved the primary endpoint of percent change from baseline (%CFB) in F-VASI with 11 mg and 22 mg doses versus ...

AbbVie Presents Data from Extensive Portfolio at the American ...

1:00–3:00 p.m.. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and. Inadequate Response to Conventional Synthetic ...

AbbVie to Present New Long-term Analysis Evaluating the ...

I'm encouraged by these data, which add to the growing body of evidence that upadacitinib may help more people living with rheumatoid arthritis ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

No new safety risks of upadacitinib were observed in this AD study compared with other AD studies. The 16-week incidence rates of TEAEs were ...